New asthma pill to target airway muscles
Researchers are developing a new asthma pill Fevipiprant to target airway muscles to decrease attacks, potentially offering the first new oral treatment for asthma in 20 years.
Read More
Tag: Fevipiprant
Novartis’ fevipiprant hailed a “game-changer” in asthma treatment
Researchers are hailing Novartis’ fevipiprant (QAW039) as a game-changer in asthma treatment after a Lancet-published trial showed its potential to significantly reduce the severity of the condition.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
